NEWTON, MA, Axena Health, a medical device company focused on female pelvic health, has closed on an additional $9.4 million in its Series A fundraising.
Cross-Border Impact Ventures (CBIV) coinvested alongside existing investors AXA IM Alts through its Global Healthcare Private Equity Strategy, KOFA Healthcare and Avestria Ventures. Donna Parr, managing director and partner at CBIV, is joining Axena Health's board of directors as part of its investment.
Axena Health is dedicated to improving the lives of women with pelvic floor disorders. Axena Health's flagship product, the Leva® Pelvic Health System, offers a novel, effective, first-line treatment for urinary incontinence (UI) and chronic fecal incontinence (FI), underreported conditions affecting over 78 million and 12 million women in the U.S. alone. Axena Health's technology enables non-invasive, drug-free treatment via precise visualization of movement in real time during pelvic floor muscle training, while monitoring usage and progress.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
